WuXi AppTec reports strong Q3 growth, divests clinical research unit

WuXi AppTec Co. released its 2025 third quarterly report, showing a total revenue of RMB32,856,716,508.86 for the first three quarters of 2025, an 18.61% year-over-year increase. Net profit attributable to owners of the company surged by 84.84% to RMB12,075,512,956.92. The company's CRDMO business model, including WuXi Chemistry, continued to drive growth, with TIDES business revenue increasing by 121.1% year-over-year to RMB7.84 billion.

Concurrently, WuXi AppTec (Shanghai) Co., Ltd., a wholly-owned subsidiary, entered into an agreement on October 24, 2025, to sell its shares in WuXi Clinical Development Services (Shanghai) Co., Ltd. and WuXi MedKey Med-Tech Development (Shanghai) Co., Ltd. to Hillhouse Investment Management for cash. This transaction aligns with the company's long-term strategy to focus on its core CRDMO business model.

The divested clinical research services generated approximately RMB1.16 billion in aggregate revenue and RMB0.09 billion in aggregate net profit for the first three quarters of 2025, accounting for about 3.5% and 0.7% of the company's total unaudited revenue and net profit, respectively, for that period.